Episodes

  • Jason Scherer: From Medical Device Idea to Market
    17 Nov 2026

    Why does it take so much time, money, and complexity to turn a good medical device idea into something physicians can actually use?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with Jason Scherer, Founder and CEO of Voltas, to explore what it really takes to bring a medical device from an idea on a napkin to a commercial product.

    Jason has spent nearly 20 years in the medical device industry, working across sales, commercialization, and company growth. Along the way, he helped bring more than 20 medical devices to market and was part of teams that ultimately experienced successful exits, including companies acquired by Johnson & Johnson.

    But the idea for Voltas came from Jason’s own experience as an inventor.

    After developing a medical device of his own, he found himself coordinating separate engineering, regulatory, coating, manufacturing, tooling, and sterilization partners, each with different priorities, timelines, and incentives. The process became expensive, fragmented, and difficult to manage.

    So he decided to build the company he wished had existed.

    Today, Voltas brings medical device development and manufacturing capabilities together under one roof, including engineering, prototyping, regulatory support, testing, tooling, manufacturing, assembly, sterilization, and commercialization. Jason shares how that integrated model can help inventors move more efficiently from concept to production while avoiding many of the mistakes he made himself.

    John and Jason also get practical about what physician inventors need to consider before pursuing a device. Is the problem meaningful enough to solve? Can the product actually be manufactured? Is it patentable? Is there reimbursement or a viable business model? And is the inventor willing to stay committed through years of iteration, setbacks, and capital requirements?

    They also look ahead at what Jason is seeing across the medical device pipeline, including the rise of sensor-based wearables, smaller catheter-based technologies, minimally invasive devices, and new challenges created by medicine in space.

    The conversation is a candid look at innovation from someone who has experienced the process from nearly every angle: selling medical devices, launching one himself, making expensive mistakes, and now helping other inventors turn their ideas into real products.

    About Jason Scherer: Jason Scherer is the Founder and CEO of Voltas and has nearly 20 years of experience in medical device sales and commercialization. He has been involved in bringing more than 20 medical devices to market and has helped build and scale companies through two successful exits. He founded Voltas after experiencing firsthand how fragmented the traditional medical device development process can be.

    About Voltas: Voltas is a vertically integrated medical device development and manufacturing company based in Minnesota. The company brings engineering, prototyping, regulatory support, testing, tooling, manufacturing, assembly, sterilization, and commercialization capabilities together under one roof, helping innovators move from concept to market with one team.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund (an internal fund with a $5k minimum) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    About Pitch Deck Analysis: For founders getting ready to raise, Pitch Deck Analysis reviews your deck like an investor would, with scoring, feedback, and recommendations on what to improve before you pitch. Use code EntrepreneurRx for a free Founder Pack with five free runs.

    Show more Show less
    28 min
  • Lyle Small: From Color-Changing Cans to Targeted Cancer Therapy
    10 Nov 2026

    How does the inventor behind the color-changing Coors Light can end up building a new approach to cancer treatment?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with Lyle Small, Founder and CEO of Lahjavida Bio, to talk about a career built around chemistry, persistence, and solving problems other people thought were too difficult.

    Lyle is a Cornell-trained bioengineer and longtime inventor who founded Chromatic Technologies, Inc., where he spent decades developing interactive inks and coatings. One of his best-known inventions became the cold-activated technology behind the mountains that turn blue on Coors Light cans.

    But that work eventually led him somewhere entirely different.

    After hiring a chemist who had worked with a dye that selectively accumulates in cancer cells, Lyle began asking a new question: if the dye could find a tumor, could it carry a treatment with it?

    That question became the foundation for Lahjavida Bio.

    The company is developing Dye-Drug Conjugates, or DDCs, synthetic small molecules that combine a tumor-seeking near-infrared dye, a cleavable linker, and a cytotoxic payload. The concept borrows from antibody-drug conjugates, but replaces the antibody with a small-molecule dye. The goal is to carry powerful cancer drugs more selectively into tumors while keeping the payload inactive during circulation and releasing it once inside the cancer cell.

    Lahjavida’s lead compound, DDC6, pairs its dye platform with MMAE, a payload already used in several approved antibody-drug conjugates. Early preclinical studies have shown tumor growth inhibition, while DDC6 has also appeared less toxic than the unprotected chemotherapy payload in the models studied to date. The company is now working to confirm those findings across additional models and determine how broadly the platform may apply across solid tumors.

    John and Lyle dig into the science behind the platform, why tumor heterogeneity makes cancer so difficult to treat, and how DDCs could eventually make combinations of powerful therapies more practical.

    But the episode is just as much about persistence as it is about cancer.

    Lyle talks about spending more than 15 years and millions of his own dollars pursuing the technology, why he continued when others might have stopped, and what decades of invention have taught him about failure, focus, humility, and being willing to think differently.

    They also discuss a life filled with calculated risk, from building companies from scratch to rafting the Grand Canyon just weeks after breaking his back, and why Lyle believes everything he has done has prepared him for the work he is doing now.

    About Lyle Small: Lyle Small is Founder and CEO of Lahjavida Bio and founder of Chromatic Technologies, Inc. (CTI). A Cornell-trained bioengineer with more than 20 patents, he developed the color-changing technology used on Coors Light cans. He has spent more than 15 years and millions of his own dollars advancing Lahjavida’s oncology platform.

    About Lahjavida Bio: Lahjavida Bio is a Colorado-based preclinical oncology company developing Dye-Drug Conjugates to deliver therapies more selectively to tumors. Spun out of CTI in 2018, the company is advancing its lead compound, DDC6, toward an investigational new drug filing. It holds four issued U.S. patents, with additional applications pending.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund (an interval fund with a $5,000 minimum) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    Show more Show less
    36 min
  • John Fees: Rethinking the Risk of Paying for College
    20 Oct 2026

    What happens when paying for college becomes a six-figure financial risk, but families have almost no safety net when something goes wrong?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with John Fees, serial entrepreneur and Co-founder and CEO of GradGuard, to talk about entrepreneurship, higher education, insurance, and the financial risks families often do not think about until it is too late.

    Fees has spent his career at the intersection of education, financial services, and technology. He previously built and sold companies to Viacom and JPMorgan Chase before co-founding Next Generation Insurance Group and launching GradGuard, a company designed to reduce the financial risks associated with college life.

    A major focus of the conversation is tuition insurance. Once a university's refund period ends, a student who has to withdraw for a covered reason may otherwise lose tuition, housing, and other academic costs already paid. GradGuard was built to provide protection against certain unexpected events and now works with more than 700 colleges and universities. Its programs have served more than 2 million students across more than 1,900 institutions.

    John and John also step back from the product itself to ask bigger questions about how America pays for education. They discuss student debt, whether the current financing system creates the right incentives, the economics of medical education, and why the cost of becoming a physician or other highly trained professional can influence career decisions long after graduation.

    The conversation then moves into entrepreneurship and insurance innovation, including why Fees believes technology and AI will pressure traditional insurance intermediaries, where specialized insurance models can still create real value, and why entrepreneurs should focus on solving problems rather than fitting into an existing industry mold.

    They close with a fascinating discussion about pattern recognition. Experience can help founders and investors recognize opportunities, but it can also create blind spots. Fees shares how his own assumptions contributed to passing on Facebook early, sparking a broader conversation about challenging what experience tells you and deliberately looking for the counterargument.

    About John Fees: John Fees is a serial entrepreneur who builds technology-enabled ventures at the intersection of financial services and education. He previously sold Y2M and Members Connect to Viacom and JPMorgan Chase, respectively, and later co-founded Next Generation Insurance Group. He holds a BS in History from Arizona State University and an MBA from Harvard Business School.

    About GradGuard: GradGuard was created around a simple problem: families can spend tens of thousands of dollars on a semester of college, yet have little protection if an unexpected illness, injury, or other covered event forces a student to withdraw. Since 2009, GradGuard has built insurance programs specifically for the risks of college life, including tuition and renters insurance. Today, the company works with more than 700 colleges and universities and has helped protect more than 2 million students across more than 1,900 institutions.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund ($5,000 minimum interval fund) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    About My Custom Wine: My Custom Wine lets you build a wine around your own taste. Tell Augustan, its AI sommelier, what you're craving, and it can blend, taste-test, and refine a custom wine from thousands of options before it is bottled with your own blend and label. Visit mycustomwine.com to build yours.

    Show more Show less
    30 min
  • Dr. Tyler Okland: Building Beyond Medicine
    13 Oct 2026
    What if becoming a doctor is only the beginning of what you’re capable of building? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Dr. Tyler Okland, double board-certified facial plastic and reconstructive surgeon and founder of Okland Facial Plastic Surgery, to talk about medicine, entrepreneurship, failure, and why doctors may be better equipped to build businesses than they realize. While completing his five-year residency in Otolaryngology–Head and Neck Surgery at Stanford, Tyler co-founded Datadoor, a real estate data company that provided institutional-grade analytics to hedge funds and investors. Rather than trying to compete broadly, Tyler and his co-founder went incredibly deep on a narrow market, eventually becoming a trusted source for some of the largest institutional investors following the company they covered. That experience ultimately helped Tyler fund his next venture: his own facial plastic surgery practice. John and Tyler discuss why specialization can be such a powerful business strategy, the financial realities facing physicians today, and why developing interests outside of medicine can provide both additional opportunity and a hedge against burnout. They also get into what Tyler believes aspiring physician-entrepreneurs often miss. You do not necessarily need another degree before starting. You need to understand what you are uniquely good at, find a real audience, build distribution, and be willing to learn as you go. Tyler shares how writing and building an audience helped create the foundation for Datadoor and why even the best product can struggle if no one knows it exists. The conversation also explores Tyler’s relationship with failure. After struggling to get into college and requiring two attempts to enter medical school, he ultimately trained at Stanford and one of the country’s leading facial plastic surgery fellowships. He credits those early setbacks with teaching him how to ask better questions, focus on what truly mattered, and become far more intentional about how he approached his career. About Dr. Tyler Okland: Dr. Tyler Okland is a double board-certified facial plastic and reconstructive surgeon and founder of Okland Facial Plastic Surgery in Denver. He earned his medical degree from the University of Colorado, completed residency in Otolaryngology–Head and Neck Surgery at Stanford, and completed fellowship training in Facial Plastic and Reconstructive Surgery at Vanderbilt. He has authored more than 30 peer-reviewed publications and is also the co-founder of Datadoor and Tone Medical Aesthetics. About Okland Facial Plastic Surgery: Okland Facial Plastic Surgery is a Denver-based practice focused on rhinoplasty, deep plane facelift surgery, and comprehensive facial rejuvenation. The practice is built around specialization and direct surgeon access, with Dr. Okland personally involved throughout consultation, surgery, and postoperative care. Dr. Okland is also the founder of Operation Breathe, through which he donates surgical care to eligible women experiencing nasal deformity, impaired breathing, or both as a result of physical domestic violence. About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund ($5,000 minimum) and selective SPVs, while partnering with founders through capital, strategic guidance, and its broader network. About Pitch Deck Analysis: For founders getting ready to raise, Pitch Deck Analysis reviews your deck like an investor would, with scoring, feedback, and recommendations on what to improve before you pitch. Use code EntrepreneurRx for a free Founder Pack with five free runs.
    Show more Show less
    25 min
  • ShadowGen: Making Voice Work Where Networks Don't
    6 Oct 2026

    What if voice communication could work anywhere a text message can get through?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with Julie Gerber, Founder & CEO of ShadowGen, and Chad Gerber, Founder & CTO, to talk about a new approach to voice communication built for the places conventional networks struggle most.

    ShadowGen is a national security technology company developing resilient voice communications for degraded, congested, and unreliable networks. Its technology reduces the bandwidth required for voice by more than 99%, opening potential applications across defense, public safety, telecommunications, tactical networks, satellite communications, and other mission-critical environments.

    The path to ShadowGen was anything but traditional. Julie began her career in global public health and disaster resilience, working with organizations including the World Health Organization before moving into music management, licensing, publishing, and technology. Chad built a career as a Gibson-endorsed artist and technologist, contributing to 10 gold and platinum records while also developing new tools for creative collaboration.

    Their worlds converged through Meloscene, a spatial computing platform built for live creative collaboration. When Julie saw how the underlying technology could address a problem she had encountered years earlier in disaster response, she asked a simple question: “Can we do that with voice?”

    That question changed the direction of what they were building.

    John, Julie, and Chad explore how ShadowGen could keep people connected when traditional communications fail, why ultra-low-bandwidth voice matters in national security and public safety, and how the technology could eventually support areas like translation, secure communications, and data analytics.

    They also get into what it is like to build a deep-tech company as a husband-and-wife team, how two radically different careers ended up converging around the same problem, and the moments that made them realize the technology could have applications far beyond music.

    About ShadowGen: ShadowGen delivers voice where conventional communications struggle. Its technology cuts the bandwidth required for voice communication by more than 99%, helping keep people connected when networks are degraded, congested, or unreliable. Built for national security and other mission-critical environments, ShadowGen is advancing resilient voice across defense, public safety, and telecommunications.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund ($5,000 minimum) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    About Deal Titan: Deal Titan is an AI-powered platform that helps investors evaluate early-stage companies faster by turning pitch decks into structured diligence reports covering the market, team, financials, competition, and key risks. Use code EntrepreneurRx for a free solo membership, including 10 full analysis reports.

    Show more Show less
    27 min
  • Kristie D'Ambrosio-Correll: Building America's Next Great Luxury Car Brand
    29 Sep 2026

    What does it take to build a new American luxury car company from the ground up?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with Kristie D'Ambrosio-Correll, Co-Founder and CEO of Dacora, to talk about what it takes to challenge one of the most established industries in the world and create a modern luxury automotive house built around beauty, craftsmanship, technology, and experience.

    Kristie's relationship with cars started long before Dacora. She grew up working on cars with her father before studying Electrical Engineering and Computer Science at MIT, where she immersed herself in artificial intelligence at the MIT Computer Science and Artificial Intelligence Lab. She later became CTO of MIRROR, helping bring the product to market and leading the company through its $500 million acquisition by lululemon. That experience gave her a firsthand look at what can happen when beautiful design and technology are built to work together.

    Today, Kristie and her husband are applying those lessons to Dacora, with the ambition of creating America's next great luxury marque. John and Kristie discuss why American ultra-luxury may be ready for a resurgence, what the automotive industry can learn from Tesla's willingness to question everything, and how Dacora's coachbuilt model allows the company to focus on the elements it believes matter most to the customer while reducing complexity, cost, and time to market.

    They also explore Kristie's evolution as a founder and leader, from a career driven by achievement and perfectionism to one shaped more by courage, resilience, and a willingness to take risks. Kristie opens up about the difficult pregnancy and birth of her daughter, how that experience changed her relationship with control and success, and why she now believes growth comes from the experiences you accumulate rather than the titles or security you hold.

    About Kristie D'Ambrosio-Correll: Kristie D'Ambrosio-Correll is the Co-Founder and CEO of Dacora. Before founding Dacora, she served as CTO of MIRROR, helping lead the company through its $500 million acquisition by lululemon. She holds bachelor's and master's degrees in Electrical Engineering and Computer Science from MIT, where she studied AI at the MIT Computer Science and Artificial Intelligence Lab. Today, Kristie and her husband combine a lifelong passion for cars with deep experience in technology and consumer products to build Dacora, reimagining the automobile around experience, personalization, and human connection.

    About Dacora: Dacora is an American luxury automotive house creating a new vision for modern transportation centered on beauty, craftsmanship, personalization, and human connection. Its coachbuilt vehicles are individually commissioned, combining timeless design and exceptional materials with an AI-native architecture designed to quietly adapt to the people it serves. Since emerging from stealth, Dacora has built a reservation pipeline exceeding its planned first year of production and begun commissioning its first Founder Series vehicles.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund ($5,000 minimum) and SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    About My Custom Wine: My Custom Wine lets you build a wine around your own taste. Tell Augustan, its AI sommelier, what you're craving, and it can blend, taste-test, and refine a custom wine from thousands of options before it is bottled with your own blend and label. Visit My Custom Wine to build yours.

    Show more Show less
    32 min
  • Chris Franks: Closing the Gap Between Medical Research and Patients
    22 Sep 2026
    What happens to breakthrough medical ideas when the science works, but no one knows how to get them out of the lab and into the hands of patients? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Chris Franks, five-time founder and CEO of Promptus, to explore one of healthcare innovation’s biggest gaps: why so much promising research never becomes a real-world product. Chris explains that the U.S. invests roughly $245 billion each year in healthcare research, yet only a small fraction of resulting technologies ever reach patients. Promptus was built to tackle that problem by identifying promising intellectual property from universities, hospitals, and physicians, then rapidly developing them toward commercialization. John and Chris dig into how Promptus evaluates thousands of technologies to find the rare opportunities that combine meaningful clinical need with a realistic regulatory, manufacturing, and commercialization pathway. They also discuss why great science alone is not enough, the challenges of working with technology transfer offices, and how Promptus aims to compress a development process that can traditionally take years into an 18-to-30-month path toward FDA submission. What makes the model especially compelling is the scale of the opportunity: thousands of technologies are already sitting inside universities and research institutions, and Promptus is building a repeatable system to identify the few with the strongest potential to become real products that can improve patient care. The conversation also goes into the founder journey. After nearly two decades of building companies, Chris shares why entrepreneurs need to get out of the office and talk to the people they are actually trying to serve, why medtech founders have to understand every stakeholder who can say “no,” and why building something valuable requires far more than having a clever idea. Chris also opens up about failure, the toll entrepreneurship can take, and one of the hardest lessons he learned along the way: you are not your company. He and John discuss separating identity from business outcomes, surviving difficult chapters, and why failure can ultimately make someone a better founder. About Chris Franks: Chris Franks is a five-time founder, CEO, and builder who has spent more than 15 years on the founder’s path. After selling his last company in 2023, he began rethinking what sustainable success looks like for founders and leaders. Today, Chris is CEO of Promptus, teaches management and leadership at the University of Colorado Denver, co-hosts the How To Founder podcast, and co-founded Denver Startup Week and the Denver Founders Network. He is also a six-time Ironman finisher. About Promptus: Promptus is a healthcare innovation platform built to close the gap between medical research and commercialization. Through its proprietary Expedited Innovation Platform, Promptus identifies high-potential IP from universities, hospitals, and physicians; acquires or licenses it directly; and develops each technology rapidly and leanly, with physicians involved from day one and a clear path toward FDA clearance in 18–30 months. Promptus is currently focused on next-generation biosensing technology designed to give people greater awareness and control over their health. About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund ($5,000 minimum) and SPVs, while partnering with founders through capital, strategic guidance, and its broader network. About Pitch Deck Analysis: For founders getting ready to raise, Pitch Deck Analysis reviews your deck like an investor would, with scoring, feedback, and recommendations on what to improve before you pitch. Use code EntrepreneurRx for a free Founder Pack with five free runs.
    Show more Show less
    23 min
  • Jeffrey Fidelman: What Founders Get Wrong About Raising Capital
    15 Sep 2026
    Why do so many founders struggle to raise capital when the basic fundraising playbook is already known? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Jeffrey Fidelman, Founder and Managing Partner of Fidelman & Company, to break down what actually works when raising capital, where founders go wrong, and why fundraising requires far more consistency and preparation than most entrepreneurs expect. Jeffrey shares how his experience in banking, venture capital, and working directly with early-stage companies exposed a major gap in the market: institutional fundraising is structured and systematic, while startup fundraising is often chaotic. That realization eventually led to Fidelman & Company’s Fundraise as a Service model, which gives founders and fund managers dedicated investor outreach infrastructure, data, and support without requiring them to build an internal investor relations team. Now, the firm is taking that methodology a step further with Fundex, a technology-enabled fundraising platform built from the CRM and investor database Fidelman & Company developed internally. Fundex is designed to make the firm’s investor intelligence and fundraising workflows more scalable and accessible to founders and fund managers managing the process themselves. Jeffrey even shares how he built the first version using AI-powered coding tools before bringing in developers to expand the platform. John and Jeffrey dig into some of the biggest mistakes founders make when pitching investors, from AI-generated decks they have not fully reviewed to unrealistic market assumptions, weak follow-up, and simply failing to ask for the investment. Jeffrey explains why founders should understand every number and claim in their deck, communicate consistently, personalize outreach, and treat fundraising like the full-time job it is. They also discuss how AI is raising the bar for early-stage companies, along with valuation, runway, how much capital founders should truly raise, and why Jeffrey generally prefers raising less capital more frequently over taking an unnecessarily large round. About Jeffrey Fidelman: Jeffrey Fidelman is the Founder and Managing Partner of Fidelman & Company, an investment bank founded in 2015 to support the fundraising and growth needs of early- to mid-stage companies and fund managers. His background spans Morgan Stanley, HSBC, early-stage venture investing, and work as an interim CFO and COO. A cum laude graduate of Harvard University, Jeffrey has helped companies navigate capital raises, acquisitions, business sales, and strategic growth initiatives. About Fidelman & Company: Fidelman & Company is a fully licensed investment bank with a team of approximately 40 people across the U.S. and Canada. Its Fundraise as a Service (FaaS) offering functions as outsourced investor relations, combining investor data, dedicated analysts, strategic support, and direct outreach on behalf of clients. The firm is also developing Fundex, a technology platform designed to bring its fundraising workflows, CRM, and investor intelligence to a broader group of founders and fund managers. About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund ($5,000 minimum) and SPVs, while partnering with founders through capital, strategic guidance, and its broader network. About Pitch Deck Analysis: For founders getting ready to raise, Pitch Deck Analysis reviews your deck like an investor would, with scoring, feedback, and recommendations on what to improve before you pitch. Use code EntrepreneurRx for a free Founder Pack with five free runs.
    Show more Show less
    22 min